TAMPA, Fla., June 13 /PRNewswire/ -- Romark Laboratories announced today that findings from research in the use of its drug, nitazoxanide, for the treatment of rotavirus could substantially reduce the impact of this viral disease affecting mostly children. Rotavirus is the leading cause of morbidity and mortality in children younger than 5 years of age, resulting in an estimated 500,000 deaths annually worldwide.